Oncologist with an interest in Health Services Research and GU Oncology

Stanford, CA
If you have ever been diagnosed with stage 0-3 breast cancer, please consider helping Stanford breast cancer researchers understand your perspectives on a new kind of clinical trial by filling out this short survey: bit.ly/3VXEQ6q #bcsm (retweets appreciated!)
6
9
1,726
How do we overcome multi-factorial barriers to receipt of high quality cancer treatments? Dr @meera_ragavan at @ASCO #ASCOQLTY22 #PharmacoEquity
Proud of Dr ⁦@meera_ragavan⁩ ⁦@CostsofCare⁩ Fellow speaking on #pharmacoEquity ⁦@ASCO⁩ #ASCOQLTY22 🙌
5
12
Pembrolizumab for non-muscle-invasive bladder cancer – is it worth the cost? @arkhaki @SWilliams_MD authors.elsevier.com/c/1eXVp…
2
11
37
Such an honor to present at #ASCO quality alongside my brilliant mentor @manalipatelmd! So grateful for opportunity to present our work and the thoughtful discussion by @MBakitas.
1
8
Divya A Parikh retweeted
Replying to @sandysrimd
@sandysrimd of @StanfordCancer discusses advances in the management of metastatic castration-resistant #ProstateCancer at the #NCCN21 Virtual Annual Conference: buff.ly/3qzcCA8 #CRPC #PCSM
2
4
Divya A Parikh retweeted
So tragic that in the wealthiest country in the world the main driving forces behind treatment preferences in #breastcancer are cost and ability to get back to work ASAP #ASCOQLTY20 @asco #healthequity
2
13
38
As #ASCO20 wraps, the US remains in turmoil. For those unable to see the inequities at the root of this strife, I will highlight 1 graph from our study. Even as we make progress over time, FAR MORE black patients die from #cancer than white patients. This is not a just society.
4
36
83
We are conducting a study on the impact of #COVID19 on cancer #providers and their practice. Help us inform ways to improve #cancercare and change policy by taking our provider survey: redcap.stanford.edu/surveys/…
4
8
Great guide for #GUcancers in uncharted times. We should consider when discussing our own practices tomorrow @Daniel_J_George @DukeGUCancer
Rethinking treatment for urology cancer. Silke Gillessen and myself giving some practical considerations #COVID19 Coming shortly in @EUplatinum
3
8
Divya A Parikh retweeted
Congratulations to the authors on publication of this patient-inclusive registry data for ROS1+ cancers. Characteristics of Patients With ROS1+ Cancers: Results From First Patient-Designed, Global, Pan-Cancer ROS1 Data Repository | JCO Oncology Practice ascopubs.org/doi/abs/10.1200…
20
38
Divya A Parikh retweeted
Huge cost savings with docetaxel vs abiraterone in HSPC. bit.ly/2lT6UMg
1
1
Divya A Parikh retweeted
Patient-reported outcomes are widely collected in routine care through Epic at @UofR, by >240k patients with >98% compliance - but clinicians only use the #PRO data 40% of the time - showing need to engage clinicians @clevinger_kc @FDAOncology @ASCO @pkluetz
4
37
81
Divya A Parikh retweeted
I'm honored to discuss plenary LBA1, a study on healthcare access, equity, & real-world data--topics of global relevance A non-traditional @ASCO plenary deserves a non-traditional approach so I'm live tweeting my talk thanks to @DukeGUCancer! #ASCO19 #ASCOhealthequity Pls share!
10
50
161